Journal Home > Just Accepted

Selenium (Se)-containing peptides may be a valuable bioactive compound to promote gut microbiota-targeted therapeutic methods for intestinal disease and hepatopathy. However, limited information is available on the utilization of selenopeptides by gut microbiota, especially Se’s function. For this purpose, the present study aimed to investigate the protective effect of selenopeptide (RYNA(Se)MNDYT, Se-P2, purity of ≥95%) and its original peptide (RYNAMNDYT, P2, purity of ≥95%) in vivo by the microbiota-metabolite axis and further analyze the potential contribution of Se biofortification to Se-P2 bioactivity. The results showed that Se-P2 exhibits a higher protective effect on lipopolysaccharide (LPS)-induced inflammation than P2, including pathology of the colon and liver, which suggested that the bioactivity of P2 was promoted by the organic combination of Se. Notably, gut microbiota composition tended to be a healthy structure by Se-P2 pretreatment in LPS-injured mice, which had a positive effect on LPS-induced gut microbiota dysbacteriosis. Additionally, only Se-P2 promoted an increase in the relative abundance of Lactobacillus, Alistipes, and Roseburia and a decrease in the relative abundance of Akkermansia, Erysipelatoclostridium, and Bacteroides in LPS-injured mice. The changes in gut microbiota were obviously correlated with the changes in metabolites and affected the metabolic pathways of valine, leucine, isoleucine, phenylalanine, tyrosine, and tryptophan biosynthesis and phenylalanine metabolism. This may be one of the key reasons for Se-P2 to exert bioactivity through the microbiota-metabolite axis. Furthermore, Se-biofortification in selenium-enriched Cordyceps militaris affected the parental proteins of Se-P2 to modulate mitogen-activated protein kinase, GPI anchored protein, and carbohydrate metabolism, translation, folding, sorting and degradation, which may contribute to the bioactivity of Se-P2. Our study provides information on the effect of Se on selenopeptides in vivo, which further promotes the prospective applications of selenopeptides as dietary supplements.

File
22-01210R1_ESM.docx (391.1 KB)
Publication history
Copyright
Rights and permissions

Publication history

Received: 26 November 2022
Revised: 30 January 2023
Accepted: 06 April 2023
Available online: 26 February 2024

Copyright

© 2024 Beijing Academy of Food Sciences.

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Return